In Vitro Activity of the New Echinocandin Antifungal, MK-0991, Against Common and Uncommon Clinical Isolates of Candida Species

Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):302-4. doi: 10.1007/pl00015011.

Abstract

A broth macrodilution method, performed as recommended by the National Committee for Clinical Laboratory Standards, was used for comparative testing of the new echinocandin antifungal agent MK-0991 and fluconazole against 50 yeast isolates belonging to 12 species of Candida. MK-0991 was shown to be highly effective against both fluconazole-susceptible and -resistant Candida spp., yielding minimum inhibitory concentrations ranging from < or = 0.19 to 0.78 microg/ml. Fungicidal activity was exerted at < or = 1.5 microg/ml for 73% of the isolates tested. This study suggests that MK-0991 has significant potential for clinical development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Candida / isolation & purification
  • Candidiasis / microbiology
  • Caspofungin
  • Echinocandins
  • Humans
  • Lipopeptides
  • Microbial Sensitivity Tests
  • Peptides*
  • Peptides, Cyclic*

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides
  • Peptides, Cyclic
  • Caspofungin